F101 - Controversies and Challenges in Contact Dermatitis
Sunday, February 18; 1:00 PM - 3:00 PM
Following this course, the attendee should be able to:
- Develop an approach to patch test negative dermatitis
- Gain insight into the immunology and pathology underlying contact dermatitis
- Identify active areas of debate and research within contact dermatitis
The session will deepen our understanding of the immunology and pathology that ultimately presents to clinicians as contact dermatitis. We will cover common challenges and considerations in contact dermatitis and patch testing that arise in clinical practice including why some patch test patients do not improve and how to manage patch test negative dermatitis.
This activity has been approved by the American Board of Dermatology (ABD) for up to 20 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org.
- Burkemper, Nicole M., MD: no financial relationships exist with commercial interests.
- Gallo, Richard L., MD, PhD: Allergan, Inc. – I(Grants/Research Funding); Colgate-Palmolive – I(Grants/Research Funding); Hoffman-La Roche Ltd. – C(H); Johnson and Johnson – A(H); MatriSys Bioscience – F(SO); Sente Labs – C(Fees);
- Mowad, Christen M., MD: AbbVie – E(S); Elsevier Inc. – B(H); UpToDate, Inc – O(IP);
- Sheinbein, David Marc, MD: no financial relationships exist with commercial interests.
- Wu, Peggy, MD: no financial relationships exist with commercial interests.
Sunday, February 18
Dr. Gallo / Hyaluronan plays a key role at the interface between innate and adaptive immunity
Dr. Burkemper / Clinicopathologic challenges in contact dermatitis--insights from a dermatopathologist's patch test clinic
Dr. Sheinbein / A few reasons why some patients with allergic skin disorders don't get any better
Dr. Mowad / Patch test negative dermatitis--what's next?